Evidence map›Paper›PMID 37610042›Full record

ArticleJournal of surgical oncology2023

Disparities in treatment and survival in early-stage hepatocellular carcinoma in California.

Sepideh Gholami, Kara T Kleber, Lauren M Perry, Mustafa Abidalhassan, Nikia R McFadden, Sarah B Bateni, Frances B Maguire, Susan L Stewart, Cyllene Morris, Moon Chen and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of surgical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Access to care and the Hispanic paradox among Hispanic patients with hepatocellular carcinoma.Clinics and research in hepatology and gastroenterology · 2025
    Article
  5. Disparities in Cancer Stage of Diagnosis by Rurality in California, 2015 to 2019.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Sepideh GholamiDivision of Surgical Oncology, Department of Surgery, Northwell Health, New Hyde Park, New York, USA.ORCID http://orcid.org/0000-0001-9294-1710
Kara T KleberDivision of Surgical Oncology, Department of Surgery, University of California Davis Medical Center, Sacramento, California, USA.
Lauren M PerryDivision of Surgical Oncology, Department of Surgery, University of California Davis Medical Center, Sacramento, California, USA.
Mustafa AbidalhassanDivision of Surgical Oncology, Department of Surgery, Northwell Health, New Hyde Park, New York, USA.
Nikia R McFaddenDivision of Surgical Oncology, Department of Surgery, University of California Davis Medical Center, Sacramento, California, USA.
Sarah B BateniDivision of Surgical Oncology, Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Frances B MaguirePublic Health Sciences, California Cancer Reporting and Epidemiologic Surveillance Program, University of California Davis Comprehensive Cancer Center, Sacramento, California, USA.
Susan L StewartPublic Health Sciences, California Cancer Reporting and Epidemiologic Surveillance Program, University of California Davis Comprehensive Cancer Center, Sacramento, California, USA.
Cyllene MorrisPublic Health Sciences, California Cancer Reporting and Epidemiologic Surveillance Program, University of California Davis Comprehensive Cancer Center, Sacramento, California, USA.
Moon ChenDivision of Hematology and Oncology, University of California Davis School of Medicine, Sacramento, California, USA.
Cameron E GaskillDivision of Surgical Oncology, Department of Surgery, University of California Davis Medical Center, Sacramento, California, USA.
Ryan P MerkowDivision of Surgical Oncology, Department of Surgery, University of Chicago Medicine, Chicago, Illinois, USA.
Theresa H KeeganDepartment of Public Health Sciences, University of California Davis, Sacramento, California, USA.

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI Gina M Dayton · 2002 to 2026
$84.9M
UC Davis Comparative Oncology Training ProgramT32CA251007 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Robert J. Canter, Xinbin Chen · 2020 to 2026
$1.8M
NCATS NIH HHS NIH #T32 CA251007NCCDPHP CDC HHS NU58DP006344NCI NIH HHS HHSN261201800009CNCI NIH HHS HHSN261201800009INCI NIH HHS HHSN261201800015CNCI NIH HHS HHSN261201800015INCI NIH HHS HHSN261201800032CNCI NIH HHS HHSN261201800032INCI NIH HHS P30 CA093373NCI NIH HHS T32 CA251007
6 · The paper itself

Abstract

BACKGROUND AND

objectivesCurative intent therapy is the standard of care for early-stage hepatocellular carcinoma (HCC). However, these therapies are under-utilized, with several treatment and survival disparities. We sought to demonstrate whether the type of facility and distance from treatment center (with transplant capabilities) contributed to disparities in curative-intent treatment and survival for early-stage HCC in California.

methodsWe performed a retrospective analysis of the California Cancer Registry for patients diagnosed with stage I or II primary HCC between 2005 and 2017. Primary and secondary outcomes were receipt of treatment and overall survival, respectively. Multivariable logistic regression and Multivariable Cox proportional hazards regression were used to evaluate associations.

resultsOf 19 059 patients with early-stage HCC, only 36% (6778) received curative-intent treatment. Compared to Non-Hispanic White patients, Hispanic patients were less likely, and Asian/Pacific Islander patients were more likely to receive curative-intent treatment. Our results showed that rural residence, public insurance, lower neighborhood SES, and care at non-National Cancer Institute-designated cancer center were associated with not receiving treatment and decreased survival.

conclusionsAlthough multiple factors influence receipt of treatment for early-HCC, our findings suggest that early intervention programs should target travel barriers and access to specialist care to help improve oncologic outcomes.

Indexed as

Carcinoma, HepatocellularHealthcare DisparitiesLiver NeoplasmsAsianCaliforniaHispanic or LatinoHumansPacific Island PeopleRetrospective StudiesCaliforniadisparitieshepatocellular carcinomaNCI-designated centertransplant centertreatment

Identifiers

PMID37610042
PMCPMC10841249

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.